TOR2A

Across TCGA pan-cancer cohorts, TOR2A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TOR2A data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TOR2A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TOR2A expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where TOR2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	II,III,IV	0.970	0.239	.005	18	view →
PDAC	OS	Median	II,III,IV	1.000	0.721	.009	6	view →
HNSC	DFS	Median	All	0.698	1.000	.020	5	view →
GBM	DFS	Median	All	0.431	0.228	.048	2	view →
LSCC	OS	Tertile	All	0.916	1.000	.034	2	view →
LUAD	DFS	Median	All	0.427	0.813	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TOR2A–CCRCC (DFS)

Open the CCRCC breakdown →